Whitepapers

Preventing contamination during routine cleaning operations requires particle-free cleaning equipment to maintain specific airborne particle levels.

Do you face challenges when it comes to the particle quality in your granulation process? In order to produce granules with the desired properties, scale-up is crucial, in addition to looking at the process parameters. After all, the path of a drug from the laboratory to production holds many a surprise. Especially in the case of particles for inhalers, the mixing process plays a decisive role. Learn what you need to consider to produce the perfect particle. This whitepaper reveals expert know-how on the mixing details, the key figures to consider and the positive effects using the practical example of inhalants.

Technology Transfer and Commercial Manufacturing of Tablets and Capsules

Problems can arise when sponsors face balancing available budget and time resources between clinical and chemistry, manufacturing, and controls (CMC) needs. Because of their high-profile importance in development, clinical needs get the emphasis, while the many CMC needs and risks may seem less critical. Unfortunately, as time passes, there is an increased risk of CMC issues becoming more complicated, time-consuming, and expensive to fix. Learn how to avoid these roadblocks by reading this white paper from Societal™ CDMO.

The relationship you build with your executive sponsor (ES) is the most critical relationship you will build with your CDMO partner and will serve as the foundation for long-term commercial success. At the core of vendor selection activities, it is vital to understand the CDMO’s flexibility and culture, models and scale of equipment, technical and analytical capabilities, regulatory support, quality system, and audit inspection history – and it is equally as vital to understand its executive sponsorship model. Learn more about why this is a vital component of your process.

Do you want to develop an oral controlled release (OCR) product? If so, you’ll quickly realize there are a lot of questions to answer. What do you want the final dosage form to do? What formulation and process approach are you going to use? What traps and roadblocks might you encounter? Understanding the options and their ramifications is the first step toward devising a plan.

An overview of Societal CDMO’s capabilities within the pharmaceutical space. Societal™ CDMO is a bi-coastal contract development and manufacturing organization (CDMO) with capabilities spanning pre-Investigational New Drug (IND) development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms with a primary focus in the area of small molecules

Central to a successful technology transfer is effective project management. This white paper discusses the role of project management at Jubilant HollisterStier in creating and executing transfer plans and the innovative solutions developed for the transfer of five COVID-19 vaccine and therapeutic fill finish manufacturing projects.

Vetting a CMO for sterile injectable fill finish means more than capacity and equipment. This white paper from Jubilant HollisterStier discusses the range of factors to consider when outsourcing manufacturing for aseptically filled and terminally sterilized products.

Specialization in ophthalmic manufacturing, demonstrated by investment in equipment, technical project management, quality systems, and regulatory compliance, ensures a safe, effective eyecare drug product. Learn what to look for in a contract manufacturing organization for ophthalmic fill finish, and how Jubilant HollisterStier can validate and scale highly efficient, replicable processes.

Developing and manufacturing complex novel oral solid dose products of highly potent compounds requires specialized expertise. Learn more about creating a safe, efficient and scalable drug development program with HPAPIs in this eBook.

Experic talks about how biopharmaceutical companies can leverage CDMO collaborations to mitigate risks and maximize the benefits of key drug development decisions.

Find out how the NanoFlowSizer’s THALIA system is capable of measuring particle size in continuous liposome manufacturing with low lipid concentrations, below 3 mg/mL.

A convenient checklist from the experts at Experic to jump-start your planning so supply challenges won’t hinder your progress! Download the checklist today and take advantage of Experic's expert tips to optimize your clinical trial supply planning.

Discover how Experic's state-of-the-art spray drying service can control the formation of consistent particles for DPI therapeutics and increase control over the resulting properties of the powder.

By partnering with a specialized CDMO, a company can leverage its expertise, state-of-the-art facilities, and streamlined processes through the entire drug development journey.

A common obstacle life sciences organizations face during clinical trials is obtaining the right patients and promoting consistent engagement. High-quality data and technology can be used to streamline clinical trials and enable omnichannel experiences.

Modern mathematical and computerized modelling tools can improve scale-up and efficiency of continuous manufacturing of oral solid dosage drugs.

This whitepaper explores the criteria for defining true quality in a CDMO partnership, including multiple product, process, and relationship variables

Biotech, BioPharma’s, CDMOs, CROs who are investigating promising nucleic acid-based drug candidates like vaccines, mAbs, and other biologics & biosimilars must go through stringent quality control checks for their molecular entities to ensure safety & efficacy of their drug candidates. Explore the best quality control workflows using QualTrak qPCR ecosystems. Learn more inside this eBook about the benefits of:

Implementing a proper contamination control strategy (CCS) helps ensure product quality and patient safety. Additionally, it is a core element of good manufacturing practices.

Analytical Method Development for Synthetic Peptide Purity and Impurities Content by UHPLC - Illustrated Case Study

KBI Biopharma has created a platform E.coli resulting in a PURE, efficient platform expression strain - PUREcoli™ - to reduce impurities and reach higher titers.

This executive summary highlights strategies that can be used to maximize long-acting parenteral formulations using nanoparticles, microspheres and in-situ forming gels.

A company focused on the treatment of advanced solid tumors, partnered with Catalent for the development, clinical trial supply and scale-up of a spray-drying program.

Discover how to use enteric polymer coatings effectively for controlled drug delivery in oral medications to enhance your drug formulations.

In pursuit of increased competitiveness and bottom-line impact, pharmaceutical manufacturers face increasing pressure to fast-track technological innovation while maintaining regulatory compliance. This e-book explores how Artificial Intelligence (AI) can unlock new levels of insights into what is causing variation in processes that can wreak havoc on your drug manufacturing performance. Learn how to use AI so you can improve your manufacturing operations in GxP environments that are capable of delivering real returns on Pharma 4.0 technology initiatives.

How to Craft a Successful Orphan Drug Designation

Oligonucleotides are a class of biotherapeutics presenting complex challenges in the development and commercialization of gene therapies. Download our paper and learn how to move your project forward.